David Ricks, Eli Lilly CEO (Carolyn Kaster/AP Images)
June 20, 2023 07:23 AM EDTUpdated 09:53 AM
Deals
R&D

Lil­ly inks $2.4B cash deal to buy DICE and its im­munol­o­gy pipeline

Kyle LaHucik

Senior Reporter

Eli Lil­ly is join­ing the “blis­ter­ing” pace of M&A this year as it bets $2.4 bil­lion in cash on DICE Ther­a­peu­tics, a pub­licly trad­ed biotech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times